We discuss the decision-making frameworks for clinical trials with multiple co-primary endpoints in a group-sequential setting. The decision-making frameworks can account for flexibilities such as a varying number of analyses, equally or unequally spaced increments of information and fixed or adaptive Type I error allocation among endpoints. The frameworks can provide efficiency, i.e., potentially fewer trial participants, than the fixed sample size designs. We investigate the operating characteristics of the decision-making frameworks and provide guidance on constructing efficient group-sequential strategies in clinical trials with multiple co-primary endpoints.
Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.
阅读:11
作者:Hamasaki Toshimitsu, Asakura Koko, Evans Scott R, Sugimoto Tomoyuki, Sozu Takashi
| 期刊: | Statistics in Biopharmaceutical Research | 影响因子: | 1.300 |
| 时间: | 2015 | 起止号: | 2015;7(1):36-54 |
| doi: | 10.1080/19466315.2014.1003090 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
